Cargando…

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

BACKGROUND: Trastuzumab is a monoclonal antibody selectively directed against Her2 and approved for the treatment of Her2 overexpressing breast cancer patients. Its proposed mechanisms of action include mediation of antibody-dependent cellular cytotoxicity (ADCC) by triggering FcγRIII on natural kil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beano, Alessandra, Signorino, Elena, Evangelista, Andrea, Brusa, Davide, Mistrangelo, Marinella, Polimeni, Maria Antonia, Spadi, Rosella, Donadio, Michela, Ciuffreda, Libero, Matera, Lina
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2415031/ https://www.ncbi.nlm.nih.gov/pubmed/18485193 http://dx.doi.org/10.1186/1479-5876-6-25

Ejemplares similares

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
por: Redana, Stefania, et al.
Publicado: (2010)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
por: Arteaga, Carlos L
Publicado: (2003)

Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study
por: Montemurro, Filippo, et al.
Publicado: (2008)

Is the Fixed-Dose Intravenous Trastuzumab Policy Warranted in Limited-Resource Settings?
por: Kassem, Loay, et al.
Publicado: (2019)

Oncological patient management on the territory: the results of a survey in the north-west of Italy
por: Baratta, Francesca, et al.
Publicado: (2022)

NK Cells and Trophoblasts: Partners in Pregnancy
por: Parham, Peter
Publicado: (2004)

How can clinical research help our understanding of trastuzumab-related cardiotoxicity?
por: Lyons, Tomás G., et al.
Publicado: (2015)

T and NK cells: two sides of tumor immunoevasion
por: Fruci, Doriana, et al.
Publicado: (2013)

Calreticulin arms NK cells against leukemia
por: Fucikova, Jitka, et al.
Publicado: (2019)

Attack of the clones: An NK cell origins story
por: Caporale, Joseph R., et al.
Publicado: (2023)

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial
por: Geurts, V.C.M., et al.
Publicado: (2023)

NK cells on the ViP stage of COVID-19
por: Masselli, Elena, et al.
Publicado: (2021)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

Trastuzumab-related cardiotoxicity: what do we know in 2020?
por: Liu, Jia, et al.
Publicado: (2020)

Commentary on CAM and NK Cells by Kazuyoshi Takeda and Ko Okumura
por: Cooper, Edwin L.
Publicado: (2004)

A role for pre-mNK cells in tumor progression
por: Rosinsky, Carolyn, et al.
Publicado: (2016)

Checkpoint immunotherapy for NK/T cell lymphoma—Time for a showdown?
por: Chan, Jason Yongsheng, et al.
Publicado: (2021)

Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit
por: Bertero, Luca, et al.
Publicado: (2020)

Re-discovering NK cell allo-reactivity in the therapy of solid tumors
por: Castagna, Luca, et al.
Publicado: (2016)

Hepatitis B vaccine and NK cells: a new player in memory
por: Hofmann, Maike, et al.
Publicado: (2021)

Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
por: Riccio, Gennaro, et al.
Publicado: (2016)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

“Universal Flu Vaccine”: Can NK Cell-mediated ADCC Tip the Scales?
por: Hassane, Maya, et al.
Publicado: (2016)

Harnessing allogeneic NK cells: improving outcomes with tailored donor lymphocyte infusion
por: McCurdy, Shannon R.
Publicado: (2022)

Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly
por: Sorscher, Steven
Publicado: (2022)

A humanized mouse model to study NK cell biology during HIV infection
por: Kim, Jocelyn T., et al.
Publicado: (2022)

Inferior vena cava prosthetic replacement in a patient with horseshoe kidney and metastatic testicular tumor: technical considerations and review of the literature
por: Rispoli, Pietro, et al.
Publicado: (2014)

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
por: Bussolati, G, et al.
Publicado: (2005)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells
por: Kopecka, Joanna, et al.
Publicado: (2011)

Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients
por: Mandili, Giorgia, et al.
Publicado: (2020)

Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer
por: Yamashita, Kohei, et al.
Publicado: (2020)

Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”
por: Baselga, J., et al.
Publicado: (2019)

White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example
por: Jackisch, Christian, et al.
Publicado: (2022)

New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
por: Rose, Jeffrey S, et al.
Publicado: (2011)

Trying to Understand NK Cell Function in vivo Points towards a Severity Score for CVID Patients
por: Wehr, Claudia
Publicado: (2016)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Where did the motor function of the cerebellum come from?
por: Coco, Marinella, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f9s9jjj39ohjo10t0mj0f4jpig